Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 1, 2023JCO Precision OncologyOpen Access

Exceptional Responses to Selpercatinib in RET Fusion–Driven Metastatic Pancreatic Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

DBDeepak BhamidipatiSYSireesha YedururiJHJason T. Huse

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Bhamidipati et al. (2023) studied this question.

synapsesocial.com/papers/6aaa61f437a4daa60571ccafhttps://doi.org/10.1200/po.23.00252
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer2019 · 2,327 citations
  2. 2FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer2011 · 7,932 citations
  3. 3Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine2013 · 6,834 citations
  4. 4Targeting the NTRK Fusion Gene in Pancreatic Acinar Cell Carcinoma: A Case Report and Review of the Literature2021 · 52 citations
  5. 5Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial2022 · 247 citations